Recombinant human CI-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis

Thrombosis and Haemostasis

Volumn 102, Issue 2, 2009, Pages 279-286

  Gurewich, Victor ^a   Pannell, Ralph ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Fibrin specificity; Fibrinolysis; Mutant ProuPA; RecC1 inhibitor

Indexed keywords

COMPLEMENT INHIBITOR; FIBRIN; MUTANT PROTEIN; PLASMIN; PLASMINOGEN; PROUROKINASE; RECOMBINANT HUMAN C1 INHIBITOR; SERINE PROTEINASE INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; ANTIPLASMIN; COMPLEMENT COMPONENT C1S INHIBITOR; FIBRINOGEN; FIBRINOLYTIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT PROTEIN; SARUPLASE; UROKINASE;

ANIMAL CELL; ARTICLE; BLOOD CLOT; BLOOD CLOT LYSIS; CONTROLLED STUDY; DEPLETION; DOG; DRUG EFFICACY; DRUG SAFETY; FIBRINOGENOLYSIS; FIBRINOLYSIS; HALF LIFE TIME; HUMAN; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; ZYMOGRAPHY; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; FIBRINOLYTIC THERAPY; GENETICS; IN VITRO STUDY; KINETICS; METABOLISM; METHODOLOGY; PHYSIOLOGY; SITE DIRECTED MUTAGENESIS;

ANIMALS; ANTIPLASMIN; COMPLEMENT C1 INACTIVATOR PROTEINS; DOGS; FIBRINOGEN; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HUMANS; KINETICS; MUTAGENESIS, SITE-DIRECTED; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT PROTEINS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 70350441945     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-09-0598     Document Type: Article

References (25)

1. Longstaff C, Thelwell C. Understanding the enzymology of fibrinolysis and improving thrombolytic therapy. FEBS Letters 2005; 579: 3302-3309. (Pubitemid 40804678)
2. Braunwald E, Knatterud GL, Passamani ER, et al. Announcement of protocol change in Thrombolysis in Myocardial Infarction Trial (letter). J Am Coll Cardiol 1987; 9: 467.
3. Meyer J, Bar F, Barth H. Randomized double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. PRIMI Trial Study Group. Lancet 1989; 1: 863-868. (Pubitemid 19107875)
4. Liu JN, Tang W, Sun ZY, et al. A site-directed mutagenesis of pro-urokinase which substantially reduces its intrinsic activity. Biochemistry 1996; 35: 14070-14076. (Pubitemid 26384402)
5. Sun Z, Liu BF, Chen Y, et al. Analysis of the forces which stabilizes the active conformation of urokinase-type plasminogen activator. Biochemistry 1998; 37: 2935-2940. (Pubitemid 28145746)
6. Liu JN, Liu JX, Liu B, et al. A prourokinase mutant which induces highly effective clot lysis without interfering with hemostasis. Circ Res 2002; 90: 757-763. (Pubitemid 34633890)
7. Gurewich V, Pannell R, Simmons-Byrd A, et al. Thrombolysis versus bleeding from hemostatic sites by a prourokinase mutant compared with tissue plasminogen activator. J Thromb Haemost 2006; 4: 1559-1565. (Pubitemid 43919184)
8. Pannell R, Kung W, Gurewich V. C1-inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis. J Thromb Haemost 2007; 5: 1047-1054. (Pubitemid 46691736)
9. Friberger P, Knos M. Plasminogen determination in human plasma. In: Chromogenic peptide substrates: chemical and clinical usage. Edinburgh: Churchill Livingston, 1979; 128-139
10. Granelli-Piperno A, Reich E. A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 1978; 148: 223-234. (Pubitemid 8376490)
11. Vassalli JD, Dayer JM, Wohlwend A, et al. Concomitant secretion of prourokinase and of a plasminogen activator specific inhibitor by cultured human monocytes macrophages. J Exp Med 1984; 159: 1653-1658. (Pubitemid 14117075)
12. Pannell R, Gurewich V. The activation of plasminogen by single-chain urokinase or by two-chain urokinase - a demonstration that single-chain urokinase has a low catalytic activity (pro-urokinase). Blood 1987; 69: 22-26. (Pubitemid 17007070)
13. Levi M, Roem D, Kamp AM, et al. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo. Thromb Haemost 1993; 69: 141-146. (Pubitemid 23041184)
14. Gurewich V, Pannell R, Broeze RJ, et al. Characterization of the intrinsic fibrinolytic properties of prourokinase through a study of plasmin resistant mutant forms produced by site specific mutagenesis of lysine 158. J Clin Invest 1988; 82: 1956-1962. (Pubitemid 19054943)
15. Liu J, Gurewich V. Fragment E-2 from fibrin substantially enhances pro-urokinase-induced glu-plasminogen activation. A kinetic study using a plasmin-resistant mutant pro-urokinase (Ala-158-rpro-UK). Biochemistry 1992; 31: 6311-6317.
16. Liu J, Pannell R, Gurewich V. A transitional state of pro-urokinase which has a higher catalytic efficiency against glu-plasminogen than urokinase. J Biol Chem 1992; 267: 15289-15292.
17. Fath-Odoubadi F, Huehns TY, Al-Muhammad A, et al. Significance of the Thrombolysis in Myocardial infarction scoring system in assessing infarct-related artery reperfusion and mortality rates after acute myocardial infarction. J Am Heart 1997; 134: 62-68. (Pubitemid 27329024)
18. Okajima K, Abe H, Binder BR. Endothelial cell injury induced by plasmin in vitro. J Lab Clin Med 1995; 126: 377-384.
19. Bennett WR, Yawn DH, Migliore PJ, et al. Activation of the complement system by recombinant tissue plasminogen activator. J Am Coll Cardiol 1987; 10: 627-632. (Pubitemid 17125630)
20. Pannell R, Black J, Gurewich V. The complementary modes of action of tissue plasminogen activator (t-PA) and pro-urokinase (pro-UK) by which their synergistic effect on clot lysis may be explained. J Clin Invest 1988; 81: 853-859. (Pubitemid 18079736)
21. Liu J, Gurewich V. A comparative study of the promotion of tissue plasminogen activator and prourokinase- induced plasminogen activation by fragments D and E-2 of fibrin. J Clin Invest 1991; 88: 2012-2017.
22. Huisman LG, van Griensven JM, Kluft C. On the role of C1-inhibitor as inhibitor of tissue-type plasminogen activator in human plasma. Thromb Haemost 1995; 73: 466-471.
23. Rao AD, Pratt B, Berke A, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J. Am Coll Cardio 1988; 11: 1-11. (Pubitemid 18029027)
24. Marder VJ, Relevance of changes in blood fibrinolytic and coagulation parameters during thrombolytic therapy. Am J Med 1987, 83: 15-19.
25. Harpel PC, Chang, TS, Verderber, E. Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma Fibrin I. Evidence for new binding sites in plasmin-degraded Fibrin I. J Biol Chem 1985; 260: 4432-4440. (Pubitemid 15092925)